Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases with high unmet medical need. The company's core business model revolves around the discovery, development, and potential commercialization of these small molecule therapies. Revenue generation is currently not from product sales, but from collaboration agreements, with future profitability dependent on successful product development and commercialization ¹. The company has incurred significant operating losses since its inception, with a net loss of $74.9 million for the year ended December 31, 2025, and $9.7 million for the year ended December 31, 2024 ². As of December 31, 2025, the accumulated deficit stood at $594.3 million ³.

The company's primary product candidate is pociredir, an oral small molecule designed to induce fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD) ⁴. Pociredir is currently in clinical development, having completed dosing in the Phase 1b PIONEER trial in adults with SCD ⁵. Clinical data from the 20 mg cohort of the PIONEER trial, as of December 23, 2025, showed a mean absolute HbF increase of 12.2% at 12 weeks of treatment, rising from a baseline of 7.1% to 19.3% ⁶. Seven of 12 patients (58%) achieved absolute HbF levels ≥20% at Week 12 ⁷. The proportion of HbF-containing red blood cells (F-cells) increased from a mean of 31% at baseline to 63% at Week 12 (n=10) ⁸. Improvements were also observed in markers of hemolysis and erythropoiesis, with indirect bilirubin decreasing by 40%, lactate dehydrogenase by 34%, RBC distribution width by 26%, and reticulocyte counts by 42% ⁹. Mean hemoglobin increased by 1.1 g/dL at Week 12, from a baseline of 7.3 g/dL to 8.4 g/dL ¹⁰. The safety profile of pociredir in the 20 mg dose cohort was generally well-tolerated, with no treatment-related serious adverse events or discontinuations due to treatment-related adverse events ¹¹.

In addition to pociredir, Fulcrum Therapeutics has a discovery approach to identify and validate cellular drug targets that modulate gene expression for genetically defined rare diseases, primarily focusing on hematology diseases ¹². This approach led to the identification of pociredir and other drug candidates. The company is exploring additional mechanisms to complement pociredir's action in inducing HbF for SCD ¹³. Preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrated tumor growth inhibition in preclinical prostate cancer models ¹⁴. However, the program for bone marrow failure syndromes will not be advanced into clinical development, with resources redirected to pociredir and core benign hematology programs ¹⁵.

For the year ended December 31, 2025, the company reported no collaboration revenue, a significant decrease from $80.0 million in collaboration revenue for the year ended December 31, 2024 ¹⁶. Total operating expenses decreased by $17.128 million, from $101.897 million in 2024 to $84.769 million in 2025 ¹⁷. This resulted in a loss from operations of $84.769 million in 2025, compared to $21.897 million in 2024 ¹⁸. Other income, net, decreased from $12.172 million in 2024 to $9.889 million in 2025 ¹⁹. The net loss for 2025 was $74.880 million, compared to $9.725 million in 2024 ²⁰. Diluted EPS for 2025 was $(1.18), compared to $(0.16) in 2024 ²¹. Cash and cash equivalents were $197.533 million as of December 31, 2025, up from $58.212 million in 2024 ²². Marketable securities were $154.773 million in 2025, down from $182.809 million in 2024 ²³. Total assets were $366.284 million in 2025, compared to $260.718 million in 2024 ²⁴. Total liabilities were $17.284 million in 2025, down from $17.684 million in 2024 ²⁵.

The decrease in collaboration revenue by $80.0 million was due to the recognition of an upfront license payment in 2024 under the now-terminated Sanofi collaboration agreement for losmapimod ²⁶. Research and development expenses decreased by $7.3 million, from $63.386 million in 2024 to $56.103 million in 2025 ²⁷. This was primarily due to a $4.6 million decrease in external R&D costs following the suspension of the losmapimod program and reduced cost-sharing reimbursement from Sanofi, partially offset by increased development costs for the pociredir PIONEER trial ²⁸. Employee compensation costs decreased by $3.9 million, including a $1.2 million decrease in stock-based compensation expense, due to reduced headcount ²⁹. General and administrative expenses decreased by $7.7 million, from $36.448 million in 2024 to $28.666 million in 2025 ³⁰, mainly due to a $4.4 million decrease in professional services costs and a $2.4 million decrease in employee compensation costs, including a $0.9 million decrease in stock-based compensation expense ³¹. Net cash used in operating activities increased to $60.065 million in 2025 from $2.218 million in 2024 ³², primarily due to the increased net loss. Net cash provided by financing activities significantly increased to $168.667 million in 2025 from $2.746 million in 2024 ³³, driven by net proceeds of $164.2 million from a December 2025 public offering of common stock and pre-funded warrants ³⁴.

During the reported period, the company completed dosing in the Phase 1b PIONEER trial for pociredir in adults with SCD ³⁵. Following an FDA clinical hold in February 2023 based on nonclinical toxicology findings, which noted similarities to other PRC2 inhibitors and reported hematological malignancies, the hold was lifted in August 2023 after submission of additional information and protocol amendments ³⁶. The protocol was amended to target patients with higher disease severity, including those with certain frequencies of vaso-occlusive crises (VOCs) and/or other specified measures of severity, previous experience with hydroxyurea, and previous experience with a stable dose of voxelotor, crizanlizumab, or L-glutamine or lack of access to these advanced therapies ³⁷. Key exclusion criteria included subjects currently on or having received hydroxyurea within 60 days prior to initiating pociredir ³⁸. The company also entered into a worldwide exclusive license agreement with CAMP4 in July 2023 for its DBA program, making an undisclosed upfront payment and becoming eligible for up to $35.0 million in development and regulatory milestone payments and up to $35.0 million in sales milestone payments, plus mid-single digit to low-double digit royalties on net sales ³⁹. In 2025, a $0.6 million preclinical milestone was achieved and paid to CAMP4 under this agreement ⁴⁰. The collaboration and license agreement with Sanofi for losmapimod was terminated following the September 2024 announcement that the Phase 3 REACH trial did not meet its primary endpoint ⁴¹.

Fulcrum Therapeutics anticipates continued significant operating losses for the foreseeable future, as it does not expect to generate revenue from product sales for several years, if at all ⁴². The company projects its expenses and operating losses to increase substantially over the next several years due to ongoing clinical development of pociredir, advancement into later-stage trials, continued preclinical studies, and the pursuit of new drug targets for genetically defined rare diseases ⁴³. Additional expenses are expected from seeking regulatory approvals, scaling up manufacturing capabilities, establishing sales and marketing infrastructure, acquiring or in-licensing assets, making milestone payments, maintaining intellectual property, and hiring additional personnel ⁴⁴.

A major growth area for the company is the rapid development of pociredir for the treatment of sickle cell disease (SCD) ⁴⁵. Following the completion of dosing in the Phase 1b PIONEER trial, the company plans to engage with the FDA and European Medicines Agency (EMA) on the design of the next trial ⁴⁶. Details regarding the design of the next trial are expected in the second quarter of 2026, after receiving meeting minutes from the End-of-Phase meeting with the FDA ⁴⁷. Pending FDA feedback, a potential registration-enabling trial is planned for initiation in the second half of 2026 ⁴⁸. Engagement with the EMA for protocol assistance and feedback on the next trial design is also planned for mid-2026 ⁴⁹. Pociredir has received orphan drug designation and fast track designation from the FDA for SCD ⁵⁰.

Another growth vector involves applying the company's discovery efforts and pursuing in-licensing or acquisition opportunities to expand its portfolio of product candidates for genetically defined rare diseases, with a primary focus on hematology diseases ⁵¹. The exclusive global license agreement with CAMP4 for its DBA program is an example of this strategy, with potential milestone payments of up to $35.0 million for development and regulatory achievements, and up to $35.0 million for sales milestones, in addition to mid-single digit to low-double digit royalties on worldwide net sales ⁵². A $0.6 million preclinical milestone was paid to CAMP4 in 2025 ⁵³. The company also plans to maximize the commercial potential of its product candidates, retaining all rights to its lead candidate and intending to use a targeted commercial infrastructure for approved rare genetically defined diseases in the United States ⁵⁴. Commercialization partnerships for certain product candidates and/or markets outside the United States may be pursued in the future ⁵⁵.

Operationally, the company expects its research and development expenses to increase in future periods as it advances pociredir, expands R&D efforts, hires additional R&D personnel, and seeks regulatory approvals ⁵⁶. Later-stage clinical development programs generally incur higher development costs due to increased size and duration of trials ⁵⁷. General and administrative expenses are also expected to increase to support continued R&D and planned commercialization activities, including establishing a sales, marketing, and distribution infrastructure, and hiring additional personnel ⁵⁸. The company does not have any manufacturing facilities and plans to continue relying on third parties for the manufacture of pociredir for future clinical trials and any future product candidates for preclinical and clinical testing, as well as for commercial manufacture if approved ⁵⁹.

Regarding capital allocation, as of December 31, 2025, the company had cash, cash equivalents, and marketable securities of approximately $352.3 million ⁶⁰. Management believes these resources will fund operating expenses and capital expenditure requirements into 2029 ⁶¹. However, this estimate is based on assumptions that may prove incorrect, potentially leading to an earlier depletion of capital resources ⁶². The company may seek additional capital due to favorable market conditions or strategic considerations, even if current funds are deemed sufficient ⁶³. In February 2024, an at-the-market (ATM) offering program was established to sell up to $100.0 million of common stock, though no shares were sold under this program as of December 31, 2025 ⁶⁴. In December 2025, the company issued and sold 11,851,853 shares of common stock at $13.50 per share and 1,111,193 pre-funded warrants at $13.499 per pre-funded warrant, generating net proceeds of $164.2 million after deducting underwriting discounts and commissions and offering expenses ⁶⁵.

The company faces structural headwinds and execution risks, including the inherent uncertainty and expense of clinical drug development, with no guarantee of success or timely completion ⁶⁶. The results of preclinical studies and early clinical trials may not predict future results, as demonstrated by the Phase 3 REACH trial for losmapimod failing its primary endpoint ⁶⁷. The potential for serious adverse events or unacceptable side effects, such as the hematological malignancies observed in nonclinical toxicology studies for pociredir, could lead to abandonment or limitation of development ⁶⁸. Enrollment delays in clinical trials, particularly for rare diseases, could also impede progress ⁶⁹. The company's reliance on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs) introduces risks related to performance, deadlines, regulatory compliance, and supply chain disruptions ⁷⁰. Furthermore, the competitive landscape in the biotechnology and pharmaceutical industries is intense, with many companies possessing greater financial resources and expertise ⁷¹. The market opportunity for product candidates in rare diseases may be smaller than estimated, requiring significant market share capture for profitability ⁷².

The company faces material risks including significant and recurring operating losses, with a net loss of $74.9 million for the year ended December 31, 2025, and an accumulated deficit of $594.3 million ⁷³. There is a substantial need for additional funding, and if capital is not raised when needed, product development or commercialization efforts could be delayed, reduced, or eliminated ⁷⁴. Clinical drug development is a lengthy, expensive, and uncertain process, with preclinical and early clinical trial results not being predictive of future outcomes, as evidenced by the failure of the Phase 3 REACH trial for losmapimod ⁷⁵. Serious adverse events or unacceptable side effects, such as the hematological malignancies observed in nonclinical toxicology studies for pociredir, could lead to development abandonment or limitations ⁷⁶. The company relies heavily on third-party contract manufacturing organizations (CMOs) and contract research organizations (CROs), and their failure to perform satisfactorily could delay development or commercialization ⁷⁷. Intellectual property protection is uncertain, with risks of challenges, invalidation, or infringement by third parties, and the potential for patent terms to be inadequate ⁷⁸. Regulatory approval processes are expensive, time-consuming, and uncertain, with no guarantee of approval or a faster process even with designations like Fast Track ⁷⁹. Post-marketing restrictions or withdrawal from the market are possible if unanticipated problems arise or regulatory requirements are not met ⁸⁰. Compliance with global privacy and data security requirements, including GDPR and evolving AI regulations, could result in additional costs, liabilities, and restrictions on data processing ⁸¹. Changes in healthcare laws and regulations, such as the Inflation Reduction Act of 2022 and proposed Medicare drug payment models, could unfavorably impact pricing and reimbursement ⁸².

Management's overall tone emphasizes a commitment to developing small molecules for genetically defined rare diseases, with a primary focus on advancing pociredir for sickle cell disease. They explicitly state the expectation of continued significant operating losses for the foreseeable future, as product sales revenue is not anticipated for several years, if at all ⁸³. Management believes that existing cash, cash equivalents, and marketable securities of $352.3 million as of December 31, 2025, will fund operating expenses and capital expenditure requirements into 2029 ⁸⁴. The three strategic priorities highlighted are: rapidly completing the clinical development of pociredir for SCD, with plans to provide details on the next trial design in the second quarter of 2026 and initiate a potential registration-enabling trial in the second half of 2026 ⁸⁵; continuing to apply discovery efforts and pursuing in-licensing or acquisition opportunities to grow the portfolio of product candidates for genetically defined rare diseases, particularly in hematology ⁸⁶; and maximizing the commercial potential of product candidates, including retaining rights to the lead candidate and planning for a targeted commercial infrastructure in the United States, while potentially seeking commercialization partnerships for ex-U.S. markets ⁸⁷.